As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global
Execs See China Deal Structure, Valuation Evolving
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
You may also be interested in...
Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.